Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01868581
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT01868529
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01868568
Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01868555
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT01865279
Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01865292
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01865331
Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01865318
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 59
- Registration Number
- NCT01865305
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 833
- Registration Number
- NCT01849289
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Vinnitsa, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath